Navelbine (Vinorelbine Tartrate)

Vinorelbine tartrate is employed in oncology to treat solid tumours that depend on microtubule dynamics.

• Non‑small cell lung cancer: helps control disease progression and may extend survival in adult patients.
• Metastatic breast cancer: reduces tumour growth and alleviates disease‑related symptoms.
• Advanced solid tumours (off‑label clinical practice): may be considered when other regimens are unsuitable.

• Vinorelbine tartrate binds to tubulin, inhibiting microtubule polymerisation during the M phase of the cell cycle. This disruption prevents proper spindle formation, leading to mitotic arrest and subsequent apoptosis of rapidly dividing cancer cells.

Vinorelbine tartrate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Anemia: lowered red blood cell levels causing fatigue.
• Nausea and vomiting: gastrointestinal upset common after dosing.
• Constipation: decreased bowel motility.
• Alopecia: hair thinning or loss.
• Fatigue: general tiredness during treatment.

Serious or Rare Side Effects

• Severe neutropenia with febrile infection.
• Pulmonary toxicity, including interstitial pneumonitis.
• Peripheral neuropathy presenting as tingling or numbness.
• Severe allergic reactions such as anaphylaxis.
• Cardiac arrhythmias or conduction disturbances.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for toxicity.

• Blood count monitoring: perform complete blood counts regularly to detect myelosuppression.
• Liver function assessment: evaluate hepatic enzymes as vinorelbine is metabolised hepatically.
• Pulmonary evaluation: avoid use in patients with pre‑existing severe lung disease.
• Concomitant myelosuppressive agents: use caution when combined with other chemotherapy that depresses bone marrow.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Vinorelbine tartrate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Other myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase vinorelbine plasma levels and toxicity.
• Drugs that prolong QT interval: may raise the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic exposure.
• Live vaccines: immunosuppression from vinorelbine may diminish vaccine efficacy.